vimarsana.com

Latest Breaking News On - Philippe bedard - Page 1 : vimarsana.com

Treadwell Therapeutics Announces A Presentation at the 2022 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor

/PRNewswire/ Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced that.

San antonioUnited statesPhilippe bedardPrincess margaret cancer centreUniversity of torontoHenryb gonzalez convention centerSan antonio breast cancer symposiumConvention centerAssociate professorStaff medical oncologistMichael tuschePhasei trialAdvanced solid tumorsNegative breast cancer expansionTreadwell therapeuticsHealth care amp hospitals

Intensity Therapeutics Announces New Clinical Data Presentation for its Lead Asset, INT230-6, in Breast Cancer, at the 2021 San Antonio Breast Cancer Symposium® in December

/PRNewswire/ Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.

New yorkUnited statesFox chase cancer centerNew york presbyterian hospital columbia university medical centerSan antonioEdna kaplanNilofer azadLillianl siuMatthew inghamSyed mahmoodLos angelesAnthonyj olszanskiPhilippe bedardMichael millerJacob thomasBristol myers squibb

vimarsana © 2020. All Rights Reserved.